• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

继发进展型多发性硬化的神经生理学和临床生物标志物:一项横断面研究。

Neurophysiological and clinical biomarkers of secondary progressive multiple sclerosis: A cross-sectional study.

作者信息

Tartaglia Matteo, Canevelli Marco, Malimpensa Leonardo, Belvisi Daniele, Baione Viola, Ferrazzano Gina, Leodori Giorgio, Berardelli Alfredo, Conte Antonella

机构信息

Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.

Department of Neurophysiology, IRCCS Neuromed, Pozzilli, Italy.

出版信息

Front Neurol. 2023 Mar 16;14:1138600. doi: 10.3389/fneur.2023.1138600. eCollection 2023.

DOI:10.3389/fneur.2023.1138600
PMID:37006502
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10060628/
Abstract

Timely diagnosis of secondary progressive multiple sclerosis (SPMS) represents a clinical challenge. The Frailty Index, a quantitative frailty measure, and the Neurophysiological Index, a combined measure of sensorimotor cortex inhibitory mechanism parameters, have recently emerged as promising tools to support SPMS diagnosis. The aim of this study was to explore the possible relationship between these two indices in MS. MS participants underwent a clinical evaluation, Frailty Index administration, and neurophysiological assessment. Frailty and Neurophysiological Index scores were found to be higher in SPMS and correlated with each other, thus suggesting that they may capture similar SPMS-related pathophysiological mechanisms.

摘要

继发性进展型多发性硬化症(SPMS)的及时诊断是一项临床挑战。衰弱指数是一种定量的衰弱测量方法,神经生理指数是感觉运动皮层抑制机制参数的综合测量方法,最近已成为支持SPMS诊断的有前景的工具。本研究的目的是探讨这两个指数在多发性硬化症中的可能关系。多发性硬化症参与者接受了临床评估、衰弱指数测定和神经生理学评估。结果发现,SPMS患者的衰弱指数和神经生理指数得分更高,且两者相互关联,这表明它们可能捕捉到了与SPMS相关的相似病理生理机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e2/10060628/6e247e5b9e62/fneur-14-1138600-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e2/10060628/6e247e5b9e62/fneur-14-1138600-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7e2/10060628/6e247e5b9e62/fneur-14-1138600-g0001.jpg

相似文献

1
Neurophysiological and clinical biomarkers of secondary progressive multiple sclerosis: A cross-sectional study.继发进展型多发性硬化的神经生理学和临床生物标志物:一项横断面研究。
Front Neurol. 2023 Mar 16;14:1138600. doi: 10.3389/fneur.2023.1138600. eCollection 2023.
2
Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers.早期诊断继发性进展型多发性硬化症:关注体液和神经生理学标志物。
J Neurol. 2021 Oct;268(10):3626-3645. doi: 10.1007/s00415-020-09964-4. Epub 2020 Jun 5.
3
Are Neurophysiological Biomarkers Able to Discriminate Multiple Sclerosis Clinical Subtypes?神经生理生物标志物能否区分多发性硬化症的临床亚型?
Biomedicines. 2022 Jan 21;10(2):231. doi: 10.3390/biomedicines10020231.
4
Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey.临床会诊中继发进展型多发性硬化症的识别与诊断:医生调查结果
Mult Scler Relat Disord. 2021 May;50:102858. doi: 10.1016/j.msard.2021.102858. Epub 2021 Feb 23.
5
Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.继发进展型多发性硬化症诊断与管理中的方法及挑战:中东欧医疗专业人员视角
Mult Scler Relat Disord. 2021 May;50:102778. doi: 10.1016/j.msard.2021.102778. Epub 2021 Jan 28.
6
Psychological flexibility, distress, and quality of life in secondary progressive multiple sclerosis: A cross-sectional study.心理灵活性、苦恼和生活质量在继发进展型多发性硬化症中的表现:一项横断面研究。
Mult Scler Relat Disord. 2022 Nov;67:104154. doi: 10.1016/j.msard.2022.104154. Epub 2022 Aug 29.
7
Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis.视网膜层变薄率作为多发性硬化进展性疾病转化的生物标志物。
Neurol Neuroimmunol Neuroinflamm. 2022 Oct 13;9(6). doi: 10.1212/NXI.0000000000200030. Print 2022 Nov.
8
Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.鞘内IgM指数与多发性硬化症的严重病程相关:临床和MRI结果
Clin Neurol Neurosurg. 2017 Sep;160:27-29. doi: 10.1016/j.clineuro.2017.05.026. Epub 2017 Jun 1.
9
Difficulty in identification of patients with active secondary progressive multiple sclerosis by clinical classification tools.临床分类工具难以识别活动期继发性进展型多发性硬化症患者。
Eur J Neurol. 2022 Apr;29(4):1100-1105. doi: 10.1111/ene.15227. Epub 2022 Jan 5.
10
Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.定义在丹麦全国人群中的继发进展型多发性硬化转化中的应用。
Mult Scler Relat Disord. 2021 Nov;56:103319. doi: 10.1016/j.msard.2021.103319. Epub 2021 Oct 10.

引用本文的文献

1
Frailty and urinary symptoms share pathophysiological mechanisms involved in disease progression in people with multiple sclerosis.衰弱与泌尿症状在多发性硬化症患者的疾病进展中具有共同的病理生理机制。
Neurol Sci. 2025 Mar 18. doi: 10.1007/s10072-025-08089-8.

本文引用的文献

1
Frailty among people with multiple sclerosis who are wheelchair users.多发性硬化症且使用轮椅患者的虚弱问题。
PLoS One. 2022 Jul 15;17(7):e0271688. doi: 10.1371/journal.pone.0271688. eCollection 2022.
2
Are Neurophysiological Biomarkers Able to Discriminate Multiple Sclerosis Clinical Subtypes?神经生理生物标志物能否区分多发性硬化症的临床亚型?
Biomedicines. 2022 Jan 21;10(2):231. doi: 10.3390/biomedicines10020231.
3
Should we still only rely on EDSS to evaluate disability in multiple sclerosis patients? A study of inter and intra rater reliability.
我们是否仍应仅依靠 EDSS 评估多发性硬化症患者的残疾程度?一项评估观察者间和观察者内可靠性的研究。
Mult Scler Relat Disord. 2021 Sep;54:103144. doi: 10.1016/j.msard.2021.103144. Epub 2021 Jul 9.
4
Early predictors of conversion to secondary progressive multiple sclerosis.继发进展型多发性硬化早期预测指标。
Mult Scler Relat Disord. 2021 Sep;54:103115. doi: 10.1016/j.msard.2021.103115. Epub 2021 Jun 26.
5
Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation.多发性硬化症患者衰弱指数的操作性定义:一项横断面研究。
Mult Scler. 2021 Oct;27(12):1939-1947. doi: 10.1177/1352458520987541. Epub 2021 Feb 10.
6
Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis.脑灰质萎缩模式与多发性硬化临床表型和进展的相关性研究。
Neurology. 2021 Mar 16;96(11):e1561-e1573. doi: 10.1212/WNL.0000000000011494. Epub 2021 Jan 13.
7
Is somatosensory temporal discrimination threshold a biomarker of disease progression in multiple sclerosis?体感时间辨别阈值是多发性硬化症疾病进展的生物标志物吗?
Clin Neurophysiol. 2020 Dec;131(12):2935-2936. doi: 10.1016/j.clinph.2020.09.012. Epub 2020 Oct 13.
8
Risk of secondary progressive multiple sclerosis: A longitudinal study.继发进展型多发性硬化症的风险:一项纵向研究。
Mult Scler. 2020 Jan;26(1):79-90. doi: 10.1177/1352458519868990. Epub 2019 Aug 9.
9
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.多发性硬化症的诊断:2017 年麦当劳标准修订版。
Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21.
10
The third-stimulus temporal discrimination threshold: focusing on the temporal processing of sensory input within primary somatosensory cortex.第三次刺激的时间辨别阈值:聚焦于初级体感皮层内感觉输入的时间处理
J Neurophysiol. 2017 Oct 1;118(4):2311-2317. doi: 10.1152/jn.00947.2016. Epub 2017 Jul 26.